Pink Sheet News

["Bernadette Goddard" <wkhlavpulsvhxm at yahoo dot com>]

ATTENTION INVESTING PUBLIC



Recent Trading Range: $.80 - $.90
Expected Trading Range: $1.50 - $2.00
ASCE . PK

BELLEVUE, WA. September 14, 2005 ? Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces it has received an initial commitment for up to $1 million in funding for continued research particularly in anti-cancer compounds and for organizational growth.

 ASCE . PK

BELLEVUE, WA. September 27th, 2005 ? Ascentia Biomedical Corporation (OTC Pink Sheets; ASCE), a leading researcher and developer of efficacious pharmaceuticals, compounds and other products, announces the addition of Dr. Philip Mease to its Scientific Advisory Board. Dr. James Clagett, President and CEO of Ascentia said, ?We are privileged to have such an internationally recognized rheumatologist who has a distinguished career in the clinical development of therapies for rheumatic diseases.  Dr. Mease?s experience in clinical drug discovery along with his respected relationship with drug regulatory agencies will greatly assist Ascentia in its drug discovery and commercialization program.?



Dr. Mease is Chief of the Rheumatology Clinical Research Division at Swedish Hospital, Clinical Professor at the University of Washington, and founder of Seattle Rheumatology Associates.  Dr. Mease graduated from Stanford University Medical School and completed his medical training at University of Washington, Seattle. He is a consultant to and member of advisory boards of several pharmaceutical and biotechnology companies including Abbott, Pfizer, Aventis, Lilly, P&G, Schering Plough, Novartis, Wyeth, Amgen, Serono, Genentech, and BiogenIDEC.  Over the past 12 years, he has been the principal investigator for over 75 clinical studies involving drugs for indications such as rheumatoid arthritis, psoriatic arthritis and psoriasis, ankylosing spondylitis, lupus, osteoarthritis, osteoporosis, and fibromyalgia.   Dr. Mease is well known and highly regarded by key drug regulatory and decision-making agencies such as the FDA, the European regulatory agency, EMEA, and the National Institute of Heath. He is significantly involved in OMERACT (Outcome Measures in Rheumatology Clinical Trials), an organization which is involved with the development and ratification of outcome measures for rheumatology indications and which aids regulatory agencies in determining appropriate measures for approval.  Dr. Mease has authored well over a hundred publications including book chapters, original articles and abstracts and frequently gives invited lectures nationally and internationally.



About Ascentia Biomedical Corporation

Our focus is SOLUTIONS through RESEARCH and DISCOVERY. Ascentia is developing and commercializing new pharmaceutical and biomedical products for application in a number of areas, including treatment for asthma, arthritis, psoriasis and cancer.  Initially, a majority of these products will be secured through direct purchase or through licensing. As the Company grows and evolves, more products will be developed internally. Ascentia is focused on therapies for cancer and diseases of inflammation.




 ASCE . PK


Forward-Looking Statements



This release may contain forward-looking statements that involve risks

and uncertainties. These statements do not constitute representations

or promises. Rather, these statements express opinions, hopes and

desires that may not be based on objective or factual criteria or

measurable results. No one should rely on such statements for any

purpose except as specifically stated



To be Removed from the list email NOSTK@Yahoo.com